Targeted therapy for lung cancer patients shows promise in extending lives

June 22, 2004

Oncologists at Rush University Medical Center, Chicago, are studying what they believe may be the wave of the future for treating patients with advanced stage lung cancer: individualized targeted therapy--easier than chemotherapy, more specialized and less toxic.

Dr. Philip D. Bonomi, director of the Division of Hematology-Oncology at Rush and principal investigator of the study, is testing whether the combination of Tarceva (erlotinib) and Celebrex (celecoxib) can shrink tumors, relieve symptoms and offer improvement and survival for patients with stage IV lung cancer.

This is the one of the first efforts involving the combination of two targeted therapies in the treatment of advanced lung cancer without chemotherapy. Molecular profiles on each patient's tumor can be evaluated to see which patients might respond better.

"This therapy is being tested in patients who have already been treated with chemotherapy, have their disease progressing, and can provide tissue for profiling. We've recruited 10 patients so far, and expect to enroll 50 among the IV sites in the study."

Targeted therapy is based on the idea that a drug will attack its target without damaging other tissue. This combination therapy is better at focusing on abnormal signals that drive cancer cells, while sparing more of the body's healthier cells. By blocking essential pathways within tumor cells, the therapy works inside of the cell with minimal effects on noncancerous cells. The drugs reduce the cancer by blocking the process by which cancer cells divide, grow and spread.

Bonomi says that Tarceva "aims to slow cancer growth by blocking the action of a molecule called the epidermal growth factor receptor, or EGFR, a protein found in the cell membrane of some cells, but found at an abnormally high rate in cancer cells. The protein triggers cells to divide at an accelerated rate, which allows the abnormal cancer cells to grow and spread.

"We hope that doing molecular profiling on each patient's tumor will enable us to identify patients who are more likely to respond and to have a favorable response. We are looking to achieve tumor shrinkage with minimal side effects. We are hopeful that this type of research will provide a kinder, gentler, more effective therapy for lung cancer patients.

"This is the most exciting thing going on in lung cancer today. For the next two decades, this will be the wave of the future in treatment."

Patients with stage IV lung cancer who receive one course of chemotherapy have side effects of nausea, vomiting and can feel worn down. This two-pill combination is not chemotherapy, and it's less toxic to the body; patients do not experience nausea and vomiting. The targeted therapy can help some patients feel better and live longer. The side effects of these pills, which are less bothersome than that of traditional chemotherapy, include an acne-like rash and diarrhea.

Bonomi says that such seriously ill lung cancer patients might be expected to live four to six months without treatment. Tarceva, one of the combination drugs, has recently been reported to increase survival. In general, survival improvement for patients with advanced stage lung cancer have been modest- adding several months to longevity. "And while that doesn't seem like a lot of time, that may mean a lot to cancer patients planning to attend a graduation, anniversary or upcoming birthday in the next few months."

Over 170,000 new incidences of lung cancer are reported every year.

The other sites in the study are Rush North Shore, Skokie, Ill.; Northwestern Memorial Hospital, Chicago, and Vanderbilt University Medical Center, Nashville.

To enroll in the study, please call 312-942-5687.
-end-


Rush University Medical Center

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.